Abstract: Poster Presentations |


Abel Rivero, MD*; Elamin Elamin, MD; Vu Nguyen, MSII; Wayne Cruse, MD; David Smith, MD
Author and Funding Information

New Jersey Medical School, Newark, NJ


Chest. 2007;132(4_MeetingAbstracts):565. doi:10.1378/chest.132.4_MeetingAbstracts.565
Text Size: A A A
Published online


PURPOSE: Inhalational lung injury (ILI) increases the incidence of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) in burn patients. Nebulized heparin (NH) and N-acetylcysteine (NA) [(NH-NA)] have been shown to decrease morbidity and mortality in both sheep models and pediatric patients. In this study, we investigated the potential benefits of NH-NA in adult patients with ILI.

METHODS: We reviewed the records of all mechanically ventilated adult subjects admitted to our burn unit over a one-year period with a diagnosis of ILI confirmed by bronchoscopy and treated with NH-NA (NH-NA group). We calculated APACHE-III scores on admission in addition to daily Lung Injury Score (LIS) for seven days. LIS was determined by averaging the scores of chest roentgenogram, PaO2/FiO2, PEEP, and respiratory system compliance. The NH-NA group was divided into five APACHE-III subgroups and matched with ILI patients who were treated in our burn unit over a four-year period before the initiation of NH-NA protocol (Non-NH-NA).

RESULTS: Nine patients in the NH-NA group and seven in the Non-NH-AC group met our inclusion and exclusion criteria and had APACHE III score greater than 35 (mean 46.66 vs. 44.86, p=0.38). In the first two ICU days mean LIS were 0.76±0.53 vs. 1.23±0.88 (p=0.08) for NH-NA and Non-NH-NA patients respectively. Mean LIS during the first week were 0.91±0.14 vs. 1.79±0.41, (p<0.01) for NH-NA and Non-NH-NA patients respectively. In addition, 11% (1/9) of the patients in NH- NA group and 43% (3/7) patients in the Non-NH- NA group died during the first ICU week.

CONCLUSION: Nebulized heparin and N-acetylcysteine reduced lung injury scores in adult burn patients with smoke inhalation injury and high APACHE III scores during the first week of treatment.

CLINICAL IMPLICATIONS: These results support the previously reported benefits of NH-AC in patients with ALI/ARDS after ILI and highlight the need to start NH-AC therapy as early as possible after ILI. Our final report will shade light on the role of the NH-AC treatment in ILI patients with lower APACHE-III scores.

DISCLOSURE: Abel Rivero, No Financial Disclosure Information; No Product/Research Disclosure Information

Wednesday, October 24, 2007

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543